Form 4: Recursion Pharma Officer Sells Shares for Tax Obligations

Recursion Pharmaceuticals' Chief R&D Commercial Officer, Najat Khan, disposed of 17,584 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit settlement.

Summary

• Najat Khan, Chief R&D Commercial Officer and Director of Recursion Pharmaceuticals, Inc. (RXRX), reported a transaction.
• On November 17, 2025, Khan disposed of 17,584 shares of Class A Common Stock.
• The disposition was made to the Issuer at a price of $4.14 per share.
• This transaction was for the purpose of satisfying tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
• Following this transaction, Khan beneficially owns 735,538 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: A score of 5 indicates neutrality. This Form 4 reports a routine, non-discretionary disposition of shares for tax purposes related to RSU vesting, which is a standard practice and does not reflect a positive or negative sentiment towards the company's performance or future prospects.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to compensation and tax obligations, common across all industries for executives receiving equity-based compensation. It does not reflect specific industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The disposition of shares for tax purposes is a routine event and generally has minimal direct impact on existing shareholders. It does not signal a change in management's confidence in the company.

Key Dates

Recommendation

This Form 4 details a non-discretionary sale of shares by an insider to cover tax obligations arising from the vesting of restricted stock units. Such transactions are routine and do not typically indicate a change in the insider's view of the company's prospects or fundamental value. Therefore, it provides no new information to warrant a change in investment recommendation; a 'hold' stance is maintained based on the neutrality of this specific filing.

Keywords

Recursion Pharmaceuticals, RXRX, Najat Khan, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Officer Transaction